Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant T-VEC and BRAF/MEK Inhibitor for Melanoma
NCT03972046Phase 2Withdrawn
- Sponsor
- TriHealth
- Start
- Jun 2019
- Primary completion
- Feb 2020
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of talimogene laherparepvec in melanoma, sponsored by TriHealth. Primary endpoint: Recurrence-Free Survival at 1 year. Planned start Jun 2019; status: withdrawn.
02
Drugs
talimogene laherparepvec
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03972046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03972046.